Studies in metastatic colorectal cancer, however, suggest that increasing the detection sensitivity for tumour KRAS mutations may actually refine patient selection for anti-EGFR monoclonal antibodies by identifying a higher proportion of patients who fail to respond to these agents28. Here, EGFR is linked to metastatic colorectal cancer.